Clinical Trial Update: MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial studying Velcade (bortezomib) for multiple myeloma patients after autologous transplantation; terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: European Society for Blood and Marrow Transplantation | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2021-10-18